Keytruda's List Price and Annual Cost
Keytruda (pembrolizumab), Merck's blockbuster PD-1 inhibitor for cancers like melanoma and lung cancer, has a U.S. wholesale acquisition cost (WAC) of $11,358 per 100 mg vial, translating to about $200,000-$250,000 annually for a typical 200 mg dose every three weeks.[1][2] Actual patient costs vary with insurance, discounts, and regimens.
How Keytruda Compares to Opdivo
Bristol Myers Squibb's Opdivo (nivolumab), the closest PD-1 rival, lists at $13,335 per 100 mg vial—higher than Keytruda's per-vial price—but annual costs align closely at $150,000-$220,000 depending on weight-based dosing (e.g., 240 mg every two weeks).[1][3] Keytruda often edges out on total spend due to less frequent dosing.
| Drug | Vial Price (100 mg) | Typical Annual Cost |
|------|----------------------|---------------------|
| Keytruda | $11,358 | $200K-$250K |
| Opdivo | $13,335 | $150K-$220K |
Matchups with PD-L1 Competitors Like Tecentriq and Imfinzi
Roche's Tecentriq (atezolizumab) costs $12,500-$18,750 per 1200 mg vial (flat dose), pushing annual estimates to $180,000-$220,000—similar to Keytruda but with combo regimens inflating totals.[1][4] AstraZeneca's Imfinzi (durvalumab) runs $7,872 per 500 mg vial, or about $150,000 yearly, making it slightly cheaper upfront but comparable in practice.[2]
Biosimilar and Generic Pressures on Pricing
No true Keytruda biosimilars exist yet in the U.S., but Opdivo faces biosimilar challenges abroad, potentially dropping prices 20-30% by 2025.[5] Keytruda's patent protection lasts until 2028 (core composition), with extensions possible, delaying U.S. competition.[6] When biosimilars launch, expect 25-40% discounts versus originators, as seen with Herceptin.
Factors Driving Price Parity Across Checkpoint Inhibitors
These drugs cluster at $150K-$250K annually due to similar manufacturing complexity and orphan drug status, but negotiations yield net prices 40-50% lower (e.g., Keytruda's $98K average net).[2] Internationally, prices halve—Keytruda at $50K-$100K in Europe—highlighting U.S. market dynamics.[7]
[1] Drugs.com - Keytruda Pricing
[2] ICER Report on Immunotherapies (2023)
[3] Drugs.com - Opdivo Pricing
[4] Drugs.com - Tecentriq Pricing
[5] FiercePharma - Opdivo Biosimilars
[6] DrugPatentWatch.com - Keytruda Patents
[7] IQVIA Global Oncology Trends (2024)